Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia

References

• Sattler M, Griffin J D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4–10
   PubMed Web of Science ®Google Scholar
• Cortes J E, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006; 106: 1306–1315
   PubMed Web of Science ®Google Scholar
• Melo J V, Barnes D J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441–453
   PubMed Web of Science ®Google Scholar
• Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker B J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653
   PubMed Web of Science ®Google Scholar
• Eaves C, Udomsakdi C, Cashman J, Barnett M, Eaves A. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma 1993; 11: 245–253
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003; 40: 80–82
   PubMed Web of Science ®Google Scholar
• Shah N P, Nicoll J M, Nagar B, Gorre M E, Paquette R L, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125
   PubMed Web of Science ®Google Scholar
• Graham S M, Jorgensen H G, Allan E, Pearson C, Alcorn M J, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325
   PubMed Web of Science ®Google Scholar
• Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?. Leuk Lymphoma 2006; 47: 1–7
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, Robey R W, Bates S E, Shukla S, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007; 21: 1267–1275
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick L J, Baird J W, Allan E K, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532–4539
   PubMed Web of Science ®Google Scholar
• Jootar S, Pornprasertsud N, Petvises S, Rerkamnuaychoke B, Disthabanchong S, Pakakasama S, et al. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. Leuk Res 2006; 30: 1493–1498
   PubMed Web of Science ®Google Scholar
• Gunsilius E. Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Adv Exp Med Biol 2003; 522: 17–24
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide C A, Deininger M W. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. Clin Lymphoma Myeloma 2007; 7: S120–S130
   PubMedGoogle Scholar
• Rousselot P, Huguet F, Rea D, Legros L, Cayuela J M, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P W, Cowan-Jacob S W, Hochhaus A, Griffin J D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345–356
   PubMed Web of Science ®Google Scholar
• Weisberg E, Catley L, Wright R D, Moreno D, Banerji L, Ray A, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007; 109: 2112–2120
   PubMed Web of Science ®Google Scholar
• Florian S, Sonneck K, Hauswirth A W, Krauth M T, Schernthaner G H, Sperr W R, et al. Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies. Leuk Lymphoma 2006; 47: 207–222
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlägel U, von Bonin M, et al. p-Glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401–408
   PubMed Web of Science ®Google Scholar
• Hoover R R, Mahon F X, Melo J V, Daley G Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068–1071
   PubMed Web of Science ®Google Scholar
• Copland M, Pellicano F, Richmond L, Allan E K, Hamilton A, Lee F Y, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergises with tyrosine kinase inhibitors. Blood, in press
   Google Scholar
• Shah N P, Tran C, Lee F Y, Chen P, Norris D, Sawyers C L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401
   PubMed Web of Science ®Google Scholar
• Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005; 90: 534–541
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Dürnberger G, Remsing Rix L L, Planyavsky M, Fernbach N V, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055–4063
   PubMed Web of Science ®Google Scholar
• Oki Y, Kantarjian H M, Gharibyan V, Jones D, O'Brien S, Verstovsek S, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899–906
   PubMed Web of Science ®Google Scholar